These forwardlooking statements include without limitation statements relating to our future operations business plans priorities research and development programs the potentially transformative benefits of SRP9001 our understanding from the FDA that the advisory committee will primarily relate to the totality of evidence supporting the conclusion that the SRP 9001 dystrophin is reasonably likely to predict clinical benefit and expected timelines plans and milestones including the regulatory action date and our understanding that the advisory committee will be held prior to the regulatory action date